Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Inclusion Criteria:
Exclusion Criteria:
Christine.Witty@emn.org+31 10 268 70 65
Sabrin.Tahri@emn.org+31 10 268 70 65
Phoenix, Arizona 85004, United States
San Diego, California 92093, United States
Orlando, Florida 32804, United States
Cleveland, Ohio 44106, United States
Philadelphia, Pennsylvania 19104, United States
Charleston, South Carolina 29425, United States
Sherbrooke, Canada
Tangshan, China
Tianjin, China
Ancona, Italy
Parma, Italy
Izmir, Turkey (Türkiye)